World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 16 December 2017
Main ID:  NCT01738178
Date of registration: 28/11/2012
Prospective Registration: Yes
Primary sponsor: McGill University Health Center
Public title: Caffeine as a Therapy for Parkinson's Disease
Scientific title: Caffeine as a Therapeutic Agent in Parkinson's Disease
Date of first enrolment: April 2014
Target sample size: 119
Recruitment status: Completed
URL:  https://clinicaltrials.gov/show/NCT01738178
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).  
Phase:  Phase 3
Countries of recruitment
Brazil Canada
Contacts
Name:     Ronald B Postuma, MD, MSc
Address: 
Telephone:
Email:
Affiliation:  Research Insitute of the MUHC
Key inclusion & exclusion criteria

Inclusion Criteria:

All patients must have idiopathic PD diagnosed as parkinsonism according to the UK brain
bank criteria, and PD considered the likeliest underlying cause according to the treating
physician. Other inclusion criteria include:

1. PD diagnosis: between 6 months and 8 years

2. Hoehn and Yahr stage I-III

3. Age at least 45 and less than 75 (to optimize survival over the 5-year trial).

4. Receiving symptomatic therapy for PD for at least 6 months. Dose must have been stable
over the previous 3 months.

Exclusion Criteria:

1. Caffeine intake >150 mg per day (i.e. more than one cup of filtered coffee per day) or
prescribed adenosine antagonists - caffeine intake will be measured by a standardized
intake questionnaire. Intake will be converted into estimated caffeine mg dose by
standard caffeine-content charts.

2. Active peptic ulcer disease, or symptomatic gastroesophageal reflux disease.

3. Supraventricular cardiac arrhythmia (such as atrial fibrillation or atrial flutter) -
Electrocardiogram will be measured at baseline to rule out supraventricular
tachycardia.

4. Uncontrolled hypertension - systolic bp >170 or diastolic bp >110 on two readings.

5. Pre-menopausal women who are not using effective methods of birth control

6. Cognitive impairment, defined as MoCA <23/30.

7. Moderate-Severe Depression, as defined by a Beck Depression Inventory score of >19.

8. Changes to antiparkinsonian medication in the last 3 months, or changes to
antiparkinsonian medication are anticipated during the next six months.

9. Current use of lithium or clozapine (pharmacokinetic interactions).



Age minimum: 45 Years
Age maximum: 75 Years
Gender: All
Health Condition(s) or Problem(s) studied
Parkinson's Disease
Intervention(s)
Drug: Placebo
Drug: Caffeine
Primary Outcome(s)
Motor manifestations associated with Parkinson's disease [Time Frame: every 6 months]
Secondary Outcome(s)
Sleep [Time Frame: every 6 motnhs]
Cognition [Time Frame: every 6 months]
Quality of life [Time Frame: every 6 months]
MDS-UPDRS components and subscales - each individual component will be assessed, including: [Time Frame: every 6 months]
Medication utilization [Time Frame: evry 6 months]
Tolerability and side effects of caffeine [Time Frame: every 6 motnhs]
Secondary ID(s)
2778
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
University Health Network, Toronto
UBC Hospital
University of Newfoundland and Eastern Health
The Ottawa Hospital
University of Calgary
Movement Disorder Clinic - Deer Lodge Centre
Pontifícia Universidade Católica do Paraná
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history